DGA S.A. Logo

DGA S.A.

Consulting, training, and EU-funded project services for public and private organizations.

DGA | WAR

Overview

Corporate Details

ISIN(s):
PLDGA0000019 (+1 more)
LEI:
259400DTDT4GWZLEL890
Country:
Poland
Address:
Poznań Towarowa 37, 61-896 Poznań
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

DGA S.A. is a consulting and advisory group with over 35 years of experience in providing innovative solutions and professional guidance. The company's core activities include business and management consulting, corporate restructuring advisory, and the implementation of comprehensive training programs for both individuals and organizations. DGA specializes in acquiring and executing projects co-financed by external sources, including European Union funds. The firm actively fosters innovation through incubation and acceleration programs for startups and social initiatives. Its diverse service portfolio also covers labor market activation, educational development programs, and specialized coaching. DGA serves a broad clientele, ranging from micro to large enterprises, public institutions, and non-governmental organizations.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 17:08
Management Discussion and Analysis
Informacje dodatkowe i komentarz Zarządu do informacji finansowych
Polish 1.5 MB
2025-11-28 17:08
Quarterly Report
Sprawozdanie finansowe DGA S.A. za III kw. 2025 r.
Polish 2.0 MB
2025-11-17 09:18
Environmental & Social Information
Podpisanie aneksu do umowy o dofinansowanie projektu DGA S.A. - Content (PL)
Polish 1.2 KB
2025-10-13 14:22
Environmental & Social Information
Wybór projektu DGA S.A. do dofinansowania - Content (PL)
Polish 1.2 KB
2025-09-30 17:17
Interim Report
Oświadczenie Zarządu
Polish 1.0 MB
2025-09-30 17:17
Audit Report / Information
Raport z przeglądu sprawozdania finansowego DGA S.A.
Polish 411.5 KB
2025-09-30 17:17
Management Discussion and Analysis
Sprawozdanie Zarządu z działalności DGA S.A. za I półrocze 2025 r
Polish 1.5 MB
2025-09-30 17:17
Annual / Quarterly Financial Statement
Sprawozdanie finansowe DGA S.A. za I półrocze 2025 r.
Polish 1.8 MB
2025-07-31 14:15
Regulatory News Service
Zawiadomienie o zejściu poniżej progu 5% ogólnej liczby głosów w Spółce - Conte…
Polish 1.8 KB
2025-07-30 15:04
Major Shareholding Notification
Zawiadomienie akcjonariusza
Polish 78.4 KB
2025-07-30 15:04
Major Shareholding Notification
Zawiadomienie o przekroczeniu progu 5% ogólnej liczby głosów w Spółce - Content…
Polish 1.2 KB
2025-07-29 13:56
Regulatory News Service
Otrzymanie podpisanego egzemplarza umowy znaczącej - Content (PL)
Polish 475 bytes
2025-07-17 15:22
Regulatory News Service
Podpisanie znaczącej umowy - Content (PL)
Polish 1.3 KB
2025-05-29 17:26
Management Discussion and Analysis
Informacje uzupełniające i komentarz Zarządu
Polish 1.5 MB
2025-05-29 17:26
Quarterly Report
Jednostkowe sprawozdanie finansowe DGA S.A. za I kw. 2025 r.
Polish 1.7 MB

Automate Your Workflow. Get a real-time feed of all DGA S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DGA S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DGA S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Advancing high-grade copper and precious metal projects from discovery to production.
Canada
COR
Cantargia Logo
Develops antibody treatments targeting IL1RAP for cancer and autoimmune/inflammatory diseases.
Sweden
CANTA
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland
CTX
Cardiff Oncology, Inc. Logo
Clinical-stage biotech developing a PLK1 inhibitor to treat resistant cancers.
United States of America
CRDF
Cardio Diagnostics Holdings, Inc. Logo
AI-powered epigenetic and genetic tests for early detection of heart disease risk.
United States of America
CDIO
Cardiol Therapeutics Inc. Logo
Develops oral cannabidiol therapies for inflammatory and fibrotic heart diseases.
United States of America
CRDL
CareDx, Inc. Logo
Precision diagnostics and surveillance solutions for the organ transplant journey.
United States of America
CDNA
Offers one-stop BPO, CRM, and staffing for admin, manufacturing, and logistics.
Japan
6070
Caris Life Sciences, Inc. Logo
Pioneering precision cancer care via AI-powered molecular profiling and diagnostics.
United States of America
CAI
Carna Biosciences, Inc. Logo
Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.
Japan
4572

Talk to a Data Expert

Have a question? We'll get back to you promptly.